Ovid Therapeutics (OVID) Cash & Equivalents (2016 - 2026)

Ovid Therapeutics' Cash & Equivalents history runs 11 years deep, the most recent figure standing at $94.1 million for Q1 2026.

• Quarterly Cash & Equivalents rose 397.04% year-over-year to $94.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $94.1 million (up 397.04% YoY) and the FY2025 annual result came in at $13.2 million, down 48.98% from the prior year.
• Cash & Equivalents was $94.1 million for Q1 2026 at Ovid Therapeutics, up from $13.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $168.6 million in Q1 2022 and bottomed at $13.2 million in Q4 2025.
• A 5-year average of $48.9 million and a median of $29.7 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents sank 77.63% — and 2026, when it jumped 397.04%.
• Ovid Therapeutics' Cash & Equivalents stood at $42.0 million in 2022, then sank by 42.07% to $24.3 million in 2023, then grew by 5.91% to $25.8 million in 2024, then slumped by 48.98% to $13.2 million in 2025, then soared by 615.15% to $94.1 million in 2026.
• Business Quant data shows OVID's Cash & Equivalents at $94.1 million in Q1 2026, $13.2 million in Q4 2025, and $20.5 million in Q3 2025.